Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Solasia Pharma KK ( (JP:4597) ).
Solasia Pharma K.K. reported its consolidated financial results for the first quarter of 2025, showing a significant increase in sales to 25 million yen, up by 111% compared to the previous year. Despite the rise in sales, the company continued to report losses with an operating loss of 296 million yen. The financial forecast for the fiscal year ending December 31, 2025, anticipates sales of 1,300 million yen, indicating a substantial year-on-year growth, although the company expects to remain unprofitable with a projected loss of 650 million yen.
More about Solasia Pharma KK
Solasia Pharma K.K. is a pharmaceutical company listed on the Tokyo Growth exchange. The company focuses on developing and commercializing innovative oncology treatments, aiming to address unmet medical needs in the cancer treatment market.
Average Trading Volume: 4,341,935
Technical Sentiment Signal: Sell
Current Market Cap: Yen7.02B
Find detailed analytics on 4597 stock on TipRanks’ Stock Analysis page.